Molecular and Clinical Features of Hepatocellular Carcinoma in Patients with HBV-HDV Infection

Abstract Hepatitis D virus (HDV) infection affects more than 10 million people worldwide, with an estimated prevalence of nearly 4.5% among HBsAg-positive individuals. Epidemiological studies have shown a significant increase in the prevalence of hepatocellular carcinoma (HCC) in patients with chronic HDV infection compared to those with chronic hepatitis B virus (HBV) mono-infection. Despite the clinical findings, data on molecular oncogenic mechanisms are limited and fragmentary. Moreover, the role of HDV in promoting the development of HCC has so far been controversial, because it is difficult to weigh the respective contributions of the two viruses. In this review, we focused on the direct oncogenic action of HDV, its role in modifying the tumor microenvironment, and the genetic signature of HDV-related HCC, comparing these features with HBV-related HCC.

[1]  P. Ferenci,et al.  Treatment of Chronic Hepatitis D with Bulevirtide—A Fight against Two Foes—An Update , 2022, Cells.

[2]  A. Gasbarrini,et al.  Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment , 2022, World journal of gastroenterology.

[3]  G. Papatheodoridis,et al.  Hepatocellular carcinoma: the virus or the liver? , 2022, Liver international : official journal of the International Association for the Study of the Liver.

[4]  F. Farinati,et al.  Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand? , 2022, International journal of molecular sciences.

[5]  Rizwan Ahamed,et al.  Hepatocellular Carcinoma in 2021: An Exhaustive Update , 2021, Cureus.

[6]  T. Pawlik,et al.  The Immunology of Hepatocellular Carcinoma , 2021, Vaccines.

[7]  G. Ioannou.  Epidemiology and risk-stratification of NAFLD-associated HCC. , 2021, Journal of hepatology.

[8]  C. Winkler,et al.  The Epigenetic Modulation of Cancer and Immune Pathways in Hepatitis B Virus-Associated Hepatocellular Carcinoma: The Influence of HBx and miRNA Dysregulation , 2021, Frontiers in Immunology.

[9]  Ming‐Lung Yu,et al.  Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues , 2021, Scientific Reports.

[10]  Ming Niu,et al.  Microarray Data Mining and Preliminary Bioinformatics Analysis of Hepatitis D Virus-Associated Hepatocellular Carcinoma , 2021, BioMed research international.

[11]  J. Zucman‐Rossi,et al.  Hepatocellular carcinoma , 1998, Nature Reviews Disease Primers.

[12]  G. Missale,et al.  Pathogenetic Mechanisms of T Cell Dysfunction in Chronic HBV Infection and Related Therapeutic Approaches , 2020, Frontiers in Immunology.

[13]  C. de Martel,et al.  The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis , 2020, Journal of hepatology.

[14]  Hashem B. El-Serag,et al.  Epidemiology of Hepatocellular Carcinoma , 2020, Hepatology.

[15]  F. Negro,et al.  Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. , 2020, Journal of hepatology.

[16]  J. Ferlay,et al.  International trends in hepatocellular carcinoma incidence, 1978–2012 , 2020, International journal of cancer.

[17]  E. Wherry,et al.  Defining ‘T cell exhaustion’ , 2019, Nature Reviews Immunology.

[18]  J. Gingold,et al.  Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma. , 2019, Trends in molecular medicine.

[19]  T. Santantonio,et al.  Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long‐term tenofovir or entecavir , 2019, Alimentary pharmacology & therapeutics.

[20]  D. Du,et al.  Small hepatitis delta antigen selectively binds to target mRNA in hepatic cells: a potential mechanism by which hepatitis D virus downregulates glutathione S-transferase P1 and induces liver injury and hepatocarcinogenesis. , 2019, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[21]  E. Seki,et al.  Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets , 2019, Seminars in Liver Disease.

[22]  G. Botti,et al.  Hepatitis delta virus and hepatocellular carcinoma: an update , 2018, Epidemiology and Infection.

[23]  Song Gao,et al.  Transforming growth factor-β and peripheral regulatory cells are negatively correlated with the overall survival of hepatocellular carcinoma , 2018, World journal of gastroenterology.

[24]  J. Kao,et al.  Review article: the prevention of hepatitis B‐related hepatocellular carcinoma , 2018, Alimentary pharmacology & therapeutics.

[25]  M. Heikenwalder,et al.  The immunology of hepatocellular carcinoma , 2018, Nature Immunology.

[26]  X. Zhang,et al.  Hepatitis B virus x protein induces epithelial-mesenchymal transition of hepatocellular carcinoma cells by regulating long non-coding RNA , 2017, Virology Journal.

[27]  G. Xia,et al.  Eradicating hepatitis B virus: The critical role of preventing perinatal transmission. , 2017, Biologicals : journal of the International Association of Biological Standardization.

[28]  Alan D. Lopez,et al.  The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level , 2017, JAMA oncology.

[29]  J. M. Salcedo,et al.  Hepatitis delta: virological and clinical aspects , 2017, Virology Journal.

[30]  J. Zhao,et al.  Change in the Treg/Th17 cell imbalance in hepatocellular carcinoma patients and its clinical value , 2017, Medicine.

[31]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[32]  J. Shindoh,et al.  Impact of Viral Etiology on Postoperative De Novo Recurrence After Hepatectomy for Hepatocellular Carcinoma in Cirrhotic Patients , 2017, Journal of Gastrointestinal Surgery.

[33]  P. Pineau,et al.  A prominent role of Hepatitis D Virus in liver cancers documented in Central Africa , 2016, BMC Infectious Diseases.

[34]  Jason A. Dominitz,et al.  Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013. , 2015, Gastroenterology.

[35]  M. Nassal.  HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B , 2015, Gut.

[36]  Z. Abbas,et al.  Hepatitis D and hepatocellular carcinoma. , 2015, World journal of hepatology.

[37]  S. Fan,et al.  Alternatively activated (M2) macrophages promote tumour growth and invasiveness in hepatocellular carcinoma. , 2015, Journal of hepatology.

[38]  M. Heikenwalder,et al.  The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets , 2015, The Journal of pathology.

[39]  B. Liao,et al.  Epidemiological, Clinical and Histological Characteristics of HBV/HDV Co-Infection: A Retrospective Cross-Sectional Study in Guangdong, China , 2014, PloS one.

[40]  G. Beatty,et al.  Immune Escape Mechanisms as a Guide for Cancer Immunotherapy , 2014, Clinical Cancer Research.

[41]  A. Galli,et al.  Molecular mechanism of hepatitis B virus-induced hepatocarcinogenesis. , 2014, World journal of gastroenterology.

[42]  G. Raimondo,et al.  Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. , 2014, Journal of hepatology.

[43]  Jaw-Town Lin,et al.  Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. , 2014, Gastroenterology.

[44]  G. Casazza,et al.  High Serum Levels of HDV RNA Are Predictors of Cirrhosis and Liver Cancer in Patients with Chronic Hepatitis Delta , 2014, PloS one.

[45]  G. Touloumi,et al.  Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. , 2013, Journal of hepatology.

[46]  Kristen Jepsen,et al.  Identification of Liver Cancer Progenitors Whose Malignant Progression Depends on Autocrine IL-6 Signaling , 2013, Cell.

[47]  M. Vinciguerra,et al.  Hepatitis delta virus induces specific DNA methylation processes in Huh‐7 liver cancer cells , 2013, FEBS letters.

[48]  T. Moliné,et al.  Oxidative stress and cancer: An overview , 2013, Ageing Research Reviews.

[49]  C. Chan,et al.  Altered Binding Site Selection of p53 Transcription Cassettes by Hepatitis B Virus X Protein , 2012, Molecular and Cellular Biology.

[50]  D. Kremsdorf,et al.  Large hepatitis delta antigen activates STAT‐3 and NF‐κB via oxidative stress , 2012, Journal of viral hepatitis.

[51]  D. Xie,et al.  TGF-β-miR-34a-CCL22 signaling-induced Treg cell recruitment promotes venous metastases of HBV-positive hepatocellular carcinoma. , 2012, Cancer cell.

[52]  Angela M. Liu,et al.  Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma , 2012, Nature Genetics.

[53]  Z. Abbas,et al.  Hepatocellular Carcinoma in Hepatitis D: Does it Differ from Hepatitis B Monoinfection? , 2012, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

[54]  M. Bouchard,et al.  The Hepatitis B Virus X Protein Elevates Cytosolic Calcium Signals by Modulating Mitochondrial Calcium Uptake , 2011, Journal of Virology.

[55]  Li Yang,et al.  Transforming growth factor-β in the gastrointestinal and hepatic tumor microenvironment. , 2011, Gastroenterology.

[56]  Xuehao Wang,et al.  Interleukin‐22 promotes human hepatocellular carcinoma by activation of STAT3 , 2011, Hepatology.

[57]  M. Buti,et al.  Clinical outcome of acute and chronic hepatitis delta over time: a long‐term follow‐up study , 2011, Journal of viral hepatitis.

[58]  Seung-Oe Lim,et al.  Hepatitis B viral X protein interacts with tumor suppressor adenomatous polyposis coli to activate Wnt/β-catenin signaling. , 2011, Cancer letters.

[59]  M. Karin,et al.  NF-κB and STAT3 – key players in liver inflammation and cancer , 2011, Cell Research.

[60]  C. Chao,et al.  Hepatitis B virus X protein prevents apoptosis of hepatocellular carcinoma cells by upregulating SATB1 and HURP expression. , 2010, Biochemical pharmacology.

[61]  H. Wedemeyer,et al.  Hepatitis Delta: Immunopathogenesis and Clinical Challenges , 2010, Digestive Diseases.

[62]  H. Zhang,et al.  Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti‐tumour immune responses , 2010, Journal of viral hepatitis.

[63]  F. Zoulim,et al.  Hepatitis B virus induced hepatocellular carcinoma. , 2009, Cancer letters.

[64]  Shou-Dong Lee,et al.  Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. , 2009, Journal of hepatology.

[65]  Chul-Yong Park,et al.  Hepatitis delta virus large antigen sensitizes to TNF-α-induced NF-κB signaling , 2009, Molecules and cells.

[66]  M. Rizzetto.  Hepatitis D: thirty years after. , 2009, Journal of hepatology.

[67]  M. Colombo,et al.  A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. , 2009, Gastroenterology.

[68]  G. Sheu,et al.  Hepatitis delta virus epigenetically enhances clusterin expression via histone acetylation in human hepatocellular carcinoma cells. , 2009, The Journal of general virology.

[69]  T. Liang.  Hepatitis B: The virus and disease , 2009, Hepatology.

[70]  M. Bouchard,et al.  Hepatitis B Virus HBx Protein Localizes to Mitochondria in Primary Rat Hepatocytes and Modulates Mitochondrial Membrane Potential , 2008, Journal of Virology.

[71]  M. Hussain,et al.  The increasing prevalence of hepatitis delta virus (HDV) infection in South London , 2008, Journal of medical virology.

[72]  A. Strongin,et al.  Interaction of Hepatitis B Viral Oncoprotein with Cellular Target HBXIP Dysregulates Centrosome Dynamics and Mitotic Spindle Formation* , 2008, Journal of Biological Chemistry.

[73]  Soo-Ho Choi,et al.  Large hepatitis delta antigen modulates transforming growth factor-beta signaling cascades: implication of hepatitis delta virus-induced liver fibrosis. , 2007, Gastroenterology.

[74]  I. Trougakos,et al.  Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases , 2006, Free radical research.

[75]  M. Serrano,et al.  The Senescent Side of Tumor Suppression , 2005, Cell cycle.

[76]  P. Angel,et al.  AP-1 subunits: quarrel and harmony among siblings , 2004, Journal of Cell Science.

[77]  Yan-Hsiung Wang,et al.  Detection of the Hepatitis B Virus X Protein (HBx) Antigen and Anti-HBx Antibodies in Cases of Human Hepatocellular Carcinoma , 2003, Journal of Clinical Microbiology.

[78]  Y. Shiratori,et al.  Synergistic activation of the serum response element-dependent pathway by hepatitis B virus x protein and large-isoform hepatitis delta antigen. , 2003, The Journal of infectious diseases.

[79]  P. Anthony.  Hepatocellular carcinoma: an overview , 2001, Histopathology.

[80]  E. Christensen,et al.  Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B , 2000, Gut.

[81]  M. Houghton,et al.  Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles , 1997, Journal of virology.

[82]  H. Netter,et al.  Pathogenesis associated with replication of hepatitis delta virus. , 1994, Infectious agents and disease.

[83]  F. Chisari,et al.  Expression of the hepatitis delta virus large and small antigens in transgenic mice , 1994, Journal of virology.

[84]  P. Marcellin,et al.  Persistent delta antigenaemia in chronic delta hepatitis and its relation with human immunodeficiency virus infection , 1992, Journal of medical virology.

[85]  J. Taylor,et al.  Hepatitis delta virus. , 2006, Virology.

[86]  H. Handa,et al.  Hepatitis Delta Virus , 2006 .

[87]  J. Sung,et al.  A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. , 1987, JAMA.

[88]  M. Brunetto,et al.  Rapidly progressive HBsAg-positive hepatitis in Italy. The role of hepatitis delta virus infection. , 1987, Journal of hepatology.

[89]  K. D. de Cock,et al.  Natural course of delta superinfection in chronic hepatitis B virus‐infected patients: Histopathologic study with multiple liver biopsies , 1986, Hepatology.

[90]  M. Rizzetto,et al.  Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope , 1986, Journal of virology.

[91]  C. Dolea,et al.  World Health Organization , 1949, International Organization.